Effectiveness and cost-effectiveness of a self-management training for patients with chronic and treatment resistant anxiety or depressive disorders: design of a multicenter randomized controlled trial by Maringa H. H. Zoun et al.
STUDY PROTOCOL Open Access
Effectiveness and cost-effectiveness of a
self-management training for patients with
chronic and treatment resistant anxiety or
depressive disorders: design of a
multicenter randomized controlled trial
Maringa H. H. Zoun1,2*, Bauke Koekkoek2,3, Henny Sinnema4, Anna D. T. Muntingh5, Anton J. L. M. van Balkom5,
Aart H. Schene6, Filip Smit4,7,8 and Jan Spijker1,2,4
Abstract
Background: Many patients with anxiety or depressive disorders achieve no remission of their symptoms after
evidence-based treatment algorithms. They develop a chronic course of the disorder. Current care for these
patients usually consists of long-term supportive contacts with a community psychiatric nurse and pharmacological
management by a psychiatrist. Data on the effectiveness of these treatments is lacking. A psychosocial
rehabilitation approach, where self-management is an increasingly important part, could be more suitable. It
focuses on the restoration of functioning and enhancement of patients’ autonomy and responsibility. Treatment
with this focus, followed by referral to primary care, may be more (cost-)effective.
Methods: A multicenter randomized controlled trial is designed for twelve participating specialized outpatient
mental health services in the Netherlands. Patients with chronic and treatment resistant anxiety or depressive
disorders, currently receiving supportive care in specialized outpatient mental health care, are asked to participate.
After inclusion, patients receive the baseline questionnaire and are randomized to the intervention group or the
usual care control group. The intervention focuses on rehabilitation and self-management and is provided by a
trained community psychiatric nurse, followed by referral to primary care. Measurements take place at 6, 12, and
18 months after baseline. This study evaluates both the effectiveness (on quality of life, symptom severity, and
empowerment), and cost-effectiveness of the intervention compared to usual care. In addition, a questionnaire is
designed to get insight in which self-management strategies patients use to manage their disorder, and in the
experiences of patients with the change of care setting.
Discussion: In this study we evaluate the effectiveness and cost-effectiveness of a self-management intervention
for patients with chronic and treatment resistant anxiety or depressive disorders in specialized outpatient mental
health care. The results of this study may provide a first ‘proof-of-concept’ in this under-researched but important
field, and might be relevant for a large group of patients in the context of a transition of the Dutch health care
system.
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Background
Anxiety and depressive disorders are among the most
common mental disorders both worldwide and in the
Netherlands. International data (the Netherlands and
other developed countries) of the lifetime prevalence of
these disorders are similar to each other. According to
results from NEMESIS-2 (Netherlands Mental Health
Survey and Incidence Study-2), the lifetime prevalence
of anxiety disorders is 19.6 %, and 18.7 % for major de-
pressive disorder [1, 2]. Also in specialized outpatient
mental health care, anxiety and depressive disorders are
common: 22.2 % of outpatients have an anxiety disorder
and 37.2 % a depressive disorder [2].
A substantial part of patients in specialized outpatient
mental health care achieve no remission of their symp-
toms after treatment that is provided in accordance with
the (inter-)national multidisciplinary guidelines [3–5].
Their disorder seems treatment-resistant [6] and they suf-
fer from a chronic course, with an estimated 41.9 %
chronicity for anxiety disorders and 24.5 % for depressive
disorders [7]. While anxiety disorders may be considered
as chronic disorders in itself [8], a depressive disorder is
defined as chronic when a depressive episode lasts more
than two years [9]. The comorbidity between anxiety and
depressive disorders is high (33–54 %) [10–12] and in-
creases with a longer duration of symptoms. Comorbidity,
in turn, increases the risk of treatment resistance and
chronicity [13, 14]. Chronic and treatment resistant
anxiety or depressive disorders are associated with more
intense suffering, increased risk of suicide, and poorer
social functioning [15, 16].
Care as usual (CAU) for patients with chronic and
treatment resistant anxiety or depressive disorders
usually consists of long-term supportive contacts with
a key clinician, which is regularly a community psy-
chiatric nurse, and pharmacological management by a
psychiatrist. This CAU often has no clear purpose,
and lacks treatment evaluation. Data on the effective-
ness is lacking [17]. Nevertheless, termination of
treatment is not considered to be an option due to
the persistent symptoms, the level of suffering, and
the absence of other treatment options. A psycho-
social rehabilitation approach, focused on specific
goals, could be more suitable [18, 19]. However, there
is no research on feasibility and effectiveness of re-
habilitation approaches for anxiety and depressive dis-
orders in specialized outpatient mental health care.
In the development of such an approach for patients
with chronic and treatment resistant anxiety or depres-
sive disorders, self-management is an increasingly im-
portant element. Self-management for long-term health
problems focuses on the restoration of functioning and
enhancement of patients’ autonomy and responsibility.
Self-management strategies are for instance: symptom
management, enacting problem-solving strategies, and
implementing learning plans [20]. We do not yet know
much about the self-management strategies used by pa-
tients with chronic and treatment resistant anxiety or
depressive disorders.
For patients with chronic and treatment resistant anx-
iety or depressive disorders in specialized outpatient
mental health care the intervention, ZemCAD (English
SemCAD; Self-management for Chronic Anxiety and
Depression) was developed, in order to offer them a dif-
ferent perspective. This is also consistent with the transi-
tion of the Dutch health care system where the aim is to
refer chronic patients to less intensive levels of care
when possible. The focus in this study is on the tran-
sition from specialized outpatient mental health care
to primary care. ZemCAD, the experimental treat-
ment, offers treatment focused on rehabilitation and
self-management, provided by a trained professional
(a community psychiatric nurse, and in some cases a
psychologist), followed by referral to primary care.
Liaison consultation with specialized mental health
care is an option if required. We compare the inter-
vention to CAU.
The objectives of this study are:
1. To assess the cost-effectiveness of ZemCAD compared
to CAU
2. To evaluate the effectiveness of ZemCAD compared
to CAU with regard to quality of life, symptom
severity, and empowerment
3. To get insight in the self-management strategies that
patients use to manage their anxiety or depressive
disorder;
4. To review the experiences of patients with a change
of care setting.
Our hypothesis is that ZemCAD is more cost-effective
than CAU. We expect that ZemCAD has outcomes just
as good and not inferior to CAU with regard to quality
of life, symptom reduction, and empowerment.
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Methods/Design
Design
In a multicenter randomized controlled trial, with
randomization at the level of patients in two parallel
groups, the protocolized ZemCAD intervention versus
care as usual is studied across twelve participating spe-
cialized outpatient mental health care services in the
Netherlands. Assessments are at baseline, 6, 12 and
18 months and assessors are blind to randomization
status.
Setting/Participants
The twelve participating specialized outpatient mental
health care services offer outpatient treatment interven-
tions for anxiety and depressive disorders, in accordance
with the (inter)national multidisciplinary guidelines. For
patients with chronic and treatment resistant anxiety or
depressive disorders, prolonged treatment (supportive
contacts with a community psychiatric nurse) is offered.
The transition from specialized outpatient mental health
care tot primary care is not considered to be an option
due to the persistent symptoms.
Inclusion criteria for the study are:
patients with anxiety or depressive disorders
according to DSM-IV;
>18 years;
> two years in specialized mental health care;
received at least one psychological treatment and at
least three medication steps according to the national
multidisciplinary guidelines on anxiety and depressive
disorders [21];
regarded by their clinicians as treatment resistant,
meaning that prolonged treatment in a specialized
outpatient mental health service according to the
professional is unlikely to improve clinical outcomes
(e.g. achieve remission);







alcohol or drugs dependence;
not fluent in Dutch language;
cognitive problems/indications for low IQ < 80.
Recruitment and randomization
Patients that are eligible for participating in the ZemCAD
study according to the inclusion and exclusion criteria are
asked to participate by their community psychiatric nurse.
This nurse informs the patient about the study and pro-
vides an information letter to take home. If the patient is
interested and consents to participate, the signed in-
formed consent is sent to the coordinating research
centre. To check the inclusion and exclusion criteria
formally, the current DSM-IV disorders present in the pa-
tient were diagnosed with the Mini-International Neuro-
psychiatric Interview (MINI interview) in the mental
health service that provides the treatment of the patient.
The MINI is a well-validated semi-structured diagnostic
interview used to establish psychiatric disorders according
to the DSM-IV [22]. After inclusion, patients receive the
baseline questionnaire. Patients and community psychi-
atric nurses are blind to the patient’s condition until they
have completed the baseline questionnaire. Then the
patient is allocated to ZemCAD or CAU, using a
randomization schedule designed by an independent stat-
istician. To evenly distribute ZemCAD/CAU across com-
munity psychiatric nurses, block randomization (block
size of four) of patients is used. Questionnaires are com-
pleted over the internet. If a patient has no access to the
internet, the questionnaires are completed on paper.
Patients are informed that participation in the study is
voluntary and that they can withdraw from the study at
any time. An overview of the study design and patient
flow is provided in Fig. 1.
Intervention
ZemCAD is based on an existing treatment protocol for
patients with chronic depression, developed at the
Amsterdam Academic Medical Center [23], adapted for
patients with chronic and treatment resistant anxiety or
depressive disorders [24]. During thirteen sessions over
twenty-six weeks patients and their families are educated
about the nature of their chronic disorder, about suicid-
ality and crises, and they learn how to cope with these
conditions and events. The trained professional and the
patient make an action plan to re-establish social con-
tacts and improve their daily living activities.
ZemCAD consists of three parts. The first part is an
introduction phase of three weeks with weekly sessions.
The goals for the professionals are to get acquainted
with the patient and family, and explain the treatment.
Patients make an individual treatment plan, identify
symptoms and daily activities, keep a log of symptoms,
and learn how they can accept lifestyle changes due to
having a chronic disease. The second part is a coaching
and treatment phase of fourteen weeks with sessions
every second week. Patients start again engaging in so-
cial activities, they are stimulated to maintain a daily
structure, and learn to use general problem solving skills
to cope with their chronic disease. The third part is the
final phase of nine weeks with sessions every three
weeks. Topics are to make an action plan on how to deal
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with crisis situations and to further practice with earlier
mentioned skills. Finally, patients are referred to primary
care. Every primary care practice is asked to select a
mental health professional who works in close collabor-
ation with the general practitioner and actively monitors
functioning of the patient. After referral to primary care,
the general practitioner is responsible for the prescrip-
tion of medication. Both mental health professional in
primary care and general practitioner have easy access
to specialized outpatient mental health services for li-
aison consultation if required.
Patients receiving ZemCAD are allocated to a new and
trained professional. This clearly marks the transition
from CAU to ZemCAD for both patient and profes-
sional. The training of the participating professionals in
ZemCAD consists of a two-day course. A prerequisite is
that the professionals study the intervention in advance.
The two-day course is provided by an expert and trainer
in cognitive behavioural therapy and motivational skills
for anxiety and depressive disorders. The training com-
bines self-study, lectures, assignments, and group discus-
sions. During the study, three additional booster sessions
were given. In addition, in each mental health service
monthly booster sessions for the professionals were
scheduled.
Usual care
Patients who are allocated to CAU continue to receive
specialized outpatient mental health care, which usually
consists of long-term supportive contacts with a com-
munity psychiatric nurse, and pharmacological manage-
ment by a psychiatrist. In most cases patients continue
care with their own community psychiatric nurse. Only
if the patient allocated to CAU receives treatment from
a community psychiatric nurse who is trained to provide
the intervention, the patient needs to switch to a differ-
ent (untrained) community psychiatric nurse. CAU may
also involve termination of treatment in specialized
Fig. 1 Study design and patient flow
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outpatient mental health care and referral to primary
care. In the ZemCAD intervention, however, this referral
is planned and anticipated within the intervention, while
in CAU the referral and termination of the treatment
only occurs when indicated.
Treatment integrity
Patients who are allocated to CAU in most cases continue
care with their current community psychiatric nurse.
Since there is no clear treatment guideline for CAU, treat-
ment integrity is not assessed in the control group. We
do, however, monitor the number of contacts patients
have with health care professionals. In the intervention
group, treatment integrity is assessed for each participat-
ing patient using a checklist that the trained professional
completes at the end of each treatment session. In this
checklist the trained professional can indicate on which
points the treatment differs from the ZemCAD protocol.
Measurements
At baseline demographics are measured. Measurements
take place 6, 12, and 18 months after baseline. Quality of
life is measured with the World Health Organization
Quality of Life instrument, Brief version (WHOQOL-
BREF) [25, 26]. The WHOQOL-BREF measures the
overall quality of life in four different areas: physical
health, psychological health, social relationships and en-
vironment. Anxiety symptoms are measured with the
Beck Anxiety Inventory (BAI) [27], a validated self-rated
questionnaire to assess the severity of anxiety symptoms.
Depression severity is measured with the Patient Health
Questionnaire (PHQ-9) [28, 29], a validated self-rated
questionnaire to assess the severity of depression symp-
toms. Empowerment is assessed using the Dutch
Empowerment Scale (Nederlandse Empowerment
Vragenlijst) [30]. Contacts with health care professionals,
medical costs, and productivity costs are measured with
the Trimbos and Institute of Medical Technology As-
sessment questionnaire for costs associated with psychi-
atric illness (TiC-P) [31]. Using this self-completion
questionnaire, direct and indirect costs of health care
utilization of patients can be assessed. In addition, the
EuroQoL (EQ-5D) [32] is used to compute Quality Ad-
justed Life Years (QALYs) gained, to be used in the cost-
utility analysis.
To get insight in self-management strategies used by
patients with chronic and treatment resistant anxiety or
depressive disorders, and experiences of patients with a
change of care setting, a questionnaire is designed. We
do this by organizing focus groups, and use concept
mapping [33] for processing the data. The questionnaire
is administered during the ZemCAD trial, to all partici-
pants, in both conditions. An overview of measurements
is provided in Table 1.
Data handling
Each participant receives a code. This code is a unique
number that is not based on personal information. The
list linking participant code and personal information is
kept in a separate file stored in a database with access
limited to designated researchers and data managers. All
our study-related information is stored in secure folders
with limited access. Paper-based data collection forms
only contain participant codes to maintain participant
confidentiality and are stored in a locked cabinet in an
area with limited access. Electronic data files are stored
on a file system with access restricted to designated re-
searchers and data managers. All results will be de-
scribed in groups of participants and data will not be
traced to a single person. Data will be stored for 5 years
after the end of inclusion. The study has low to negli-
gibly risks therefore no data monitoring committee is
assigned. Only the designated researchers, or persons
assigned by them, will have access to the final data set.
Authors of the final manuscript have made substantial
contributions to the design, conduction, interpretation
and reporting of the trial. We will not use professional
writers. Participants, funders and involved professionals
will receive a summary of the study results. Final results
will be presented via publications and presentations.
Sample size
The feasibility of our trial is evaluated in a pilot study,
which was carried out within one of the participating
mental health services. Based on the number of included
patients in this pilot and the number of services participat-
ing, we expect to be able to include 130–180 patients in
our trial. This is enough to detect a standardized mean
difference of d ≥ 0.50 in a 2-tailed test at α = 0.05 and with
a power of (1-β) = 0.80. However, we do not expect such
large differences between the conditions on any of the
Table 1 Overview of measurements





Quality of life (WHOQOL-
BREF)
x x x x
Anxiety (BAI) x x x x
Depression (PHQ-9) x x x x
Empowerment (Dutch
Empowerment Scale)
x x x x
Health care costs (TiC-P) x x x x
Health care costs (EQ-5D) x x x x
Questionnaire about self-
management strategies
and experiences with a
change of care setting
x
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outcomes. With regard to the hypotheses about the clin-
ical effects we assume non-inferiority rather than super-
iority and with n = 130 the non-inferiority margin would
be as large as d = 0.45 (one sided), which is uninformative.
That said, our main hypothesis requires health-economic
decision-making. In that context it is more customary to
take a probabilistic medical decision-making approach
and do not rely on statistical techniques to test
hypotheses.
Statistical analysis
Descriptive statistics are used for presenting the demo-
graphics of the sample. All outcome analyses are con-
ducted in agreement with the intention-to-treat (ITT)
principle, as required by the CONSORT statement [34].
To that end, we use linear mixed-effects models. If differ-
ences in baseline data are present, we adjust for relevant
baseline characteristics, by including baseline variables as
covariates in the model. To see how effects develop over
time we also model interactions of the treatment with
time in the linear mixed-effects models. All analyses are
conducted in SPSS 22 and Stata 13.1 or later versions.
Economic evaluation
The health economic evaluation is conducted in agree-
ment with the CHEERS statement [35]. Healthcare
utilization is measured and costs are calculated using
standard unit prices (for the reference year 2014) pub-
lished in the Dutch costing guideline [36]. In addition,
data on (increased or decreased) productivity due to
changes in the number of hours worked per week and
accounting for absenteeism and presenteeism are valued
using the mean per-capita gross income. The difference
between ZemCAD and CAU in terms of health gains are
expressed in QALYs, based on the EQ-5D. Non-
parametric bootstrapping is used to estimate the uncer-
tainty surrounding costs and effects. On that basis, prob-
abilistic statements can be made about the likelihood
that, relative to usual care, the new intervention (1) costs
more and is associated with QALY gains, (2) costs more
and is associated with QALY losses, (3) costs less and is
associated with QALY losses, or (4) costs less and is as-
sociated with QALY gains. Obviously scenario 2 is the
least attractive and in that case maintaining the old
(current) health care system is the best option as seen
from a (narrow) health-economics perspective, but al-
ways contingent on further medical-ethical consider-
ations. In case of scenario 4 the new health care system
is the best option as viewed from a health-economics
perspective. However, we often end up in scenario 1: we
pay more and get more QALYs. This could be an accept-
able scenario, but raises the question how much we are
willing to pay for the additional QALY gains. In such a
scenario we therefore also consider a range of willingness-
to-pay (WTP) ceilings while using the so-called accept-
ability curve, where the probability of cost-effectiveness is
plotted against various WTP ceilings. The incremental
cost-effectiveness ratios (ICER) acceptability curve helps
in the decision whether ZemCAD should or should not be
considered as cost-effective from a probabilistic medical
decision-making perspective. The health-economic evalu-
ation is completed with sensitivity analyses focusing on
uncertainties in major cost-drivers, and is intended to
show how robust the results of the cost-effectiveness ana-
lysis are under uncertainty. It is worth re-emphasising that
in addition to health-economic considerations other con-
siderations, such as medical-ethical considerations and pa-
tients’ preferences, ought to play a role in medical
decision-making.
Discussion
This article describes a protocol for a multicenter ran-
domized controlled trial on the effectiveness and cost-
effectiveness of a self-management intervention for pa-
tients with chronic and treatment resistant anxiety or de-
pressive disorders in specialized outpatient mental health
care. In this study we evaluate the cost-effectiveness of
ZemCAD compared to CAU. We also explore the effects
of the ZemCAD intervention compared to CAU on qual-
ity of life, depressive and anxiety symptom severity, and
empowerment. Furthermore we like to shed light on the
self-management strategies that patients use to cope with
their chronic and treatment resistant anxiety or depressive
disorder, and experiences of patients with a change of care
setting. Given the fact that there are hardly any evidence-
based interventions for patients with these disorders, and
the need to make cost-effective use of scarce resources,
the results of this study may provide a first ‘proof-of-con-
cept’ in this under-researched but important field. More-
over the results of this study might be relevant for a large
group of patients in the context of a transition of the
Dutch health care system. In this study we focus on the
transition from specialized outpatient mental health care
to primary care.
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